CIBC Asset Management Inc Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

CIBC Asset Management Inc lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 9.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 256,237 shares of the medical research company’s stock after purchasing an additional 22,941 shares during the quarter. CIBC Asset Management Inc owned about 0.14% of IQVIA worth $50,963,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IQV. Hanson & Doremus Investment Management boosted its holdings in shares of IQVIA by 300.0% in the 1st quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock worth $29,000 after purchasing an additional 108 shares during the period. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA in the 1st quarter worth approximately $36,000. Live Oak Investment Partners purchased a new position in IQVIA during the 4th quarter valued at $41,000. Headlands Technologies LLC boosted its holdings in IQVIA by 62.3% during the 1st quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Finally, MBM Wealth Consultants LLC purchased a new position in IQVIA during the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 86.82% of the company’s stock.

IQVIA Stock Up 0.8 %

Shares of IQV traded up $1.70 during trading hours on Monday, hitting $224.33. The company had a trading volume of 682,600 shares, compared to its average volume of 1,013,287. The company has a market capitalization of $41.08 billion, a PE ratio of 38.61, a price-to-earnings-growth ratio of 2.27 and a beta of 1.37. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 2.16. IQVIA Holdings Inc. has a one year low of $165.75 and a one year high of $241.86. The company’s fifty day moving average price is $220.55 and its two-hundred day moving average price is $207.86.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.09 by $0.13. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. The firm had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.70 billion. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 9.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on IQV shares. Truist Financial boosted their price objective on IQVIA from $244.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Citigroup boosted their price objective on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. StockNews.com assumed coverage on IQVIA in a report on Thursday, August 17th. They set a “hold” rating for the company. Morgan Stanley lifted their target price on IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Wednesday, August 2nd. Finally, Stifel Nicolaus lifted their target price on IQVIA from $255.00 to $281.00 and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $251.38.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.